Table 8.

Summary of the incidence of adverse events

Parameter	120 μg	240 μg	Placebo
Number of patients evaluated	36	41	35
Number of patients who experienced adverse events	27 (75.0 %)	36 (87.8 %)	28 (80.0 %)
Number of patients who experienced serious adverse events	3 (8.3 %)	4 (9.8 %)	1 (2.9 %)
Number of patients who discontinued the study treatment due to adverse events	4 (11.1 %)	7 (17.1 %)	0 (0.0 %)
Number of patients who interrupted the study treatment due to adverse events	0 (0.0 %)	2 (4.9 %)	0 (0.0 %)

(): Incidence rate